Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Preladenant in Moderate to Severe Parkinson's Disease
NCT01215227Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2010
- Primary completion
- Jul 2013
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of preladenant in Parkinson's disease (PD), sponsored by Merck & Co.. Started Nov 2010; status: terminated.
02
Drugs
preladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01215227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01215227.